233 related articles for article (PubMed ID: 3053207)
21. Carboplatin or iproplatin in advanced non-small cell lung cancer: a Cancer and Leukemia Group B Study.
Kreisman H; Ginsberg S; Propert KJ; Richards F; Graziano S; Green M
Cancer Treat Rep; 1987 Nov; 71(11):1049-52. PubMed ID: 2824045
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
[TBL] [Abstract][Full Text] [Related]
23. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Ozols RF; Bundy BN; Greer BE; Fowler JM; Clarke-Pearson D; Burger RA; Mannel RS; DeGeest K; Hartenbach EM; Baergen R;
J Clin Oncol; 2003 Sep; 21(17):3194-200. PubMed ID: 12860964
[TBL] [Abstract][Full Text] [Related]
24. Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin.
Edmonson JH; Hartmann LC; Long HJ; Colon-Otero G; Fitch TR; Jefferies JA; Braich TA; Maples WJ
Cancer; 1992 Nov; 70(10):2529-39. PubMed ID: 1423182
[TBL] [Abstract][Full Text] [Related]
25. Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients.
Misset JL; Vennin P; Chollet PH; Pouillart P; Laplaige PH; Frobert JL; Castera D; Fabro M; Langlois D; Cortesi E; Lucas V; Gamelin E; Laadem A; Otero J
Ann Oncol; 2001 Oct; 12(10):1411-5. PubMed ID: 11762813
[TBL] [Abstract][Full Text] [Related]
26. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study.
Alberts DS; Dahlberg S; Green SJ; Garcia D; Hannigan EV; O'Toole R; Stock-Novack D; Surwit EA; Malviya VK; Jolles CJ
Cancer; 1993 Jan; 71(2 Suppl):618-27. PubMed ID: 8420685
[TBL] [Abstract][Full Text] [Related]
27. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
[TBL] [Abstract][Full Text] [Related]
28. Carboplatin versus cisplatin in ovarian cancer.
Alberts DS
Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
[TBL] [Abstract][Full Text] [Related]
29. A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain.
Hidalgo M; Mendiola C; López-Vega JM; Castellano D; Mendez M; Batiste-Alenton E; López-Brea M; Belon J; Batista JN; Cortés-Funes H
Cancer; 1998 Aug; 83(4):719-25. PubMed ID: 9708936
[TBL] [Abstract][Full Text] [Related]
30. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.
Di Re F; Bohm S; Oriana S; Spatti GB; Zunino F
Cancer Chemother Pharmacol; 1990; 25(5):355-60. PubMed ID: 2306797
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
[TBL] [Abstract][Full Text] [Related]
33. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study.
Lancet; 1998 Nov; 352(9140):1571-6. PubMed ID: 9843101
[TBL] [Abstract][Full Text] [Related]
34. The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer.
Vermorken JB
Int J Gynecol Cancer; 2001; 11 Suppl 1():21-30. PubMed ID: 11488999
[TBL] [Abstract][Full Text] [Related]
35. A pilot study of carboplatin (JM8, CBDCA) and chlorambucil in combination for advanced ovarian cancer.
Harding M; Kennedy R; Mill L; MacLean A; Duncan I; Kennedy J; Soukop M; Kaye SB
Br J Cancer; 1988 Nov; 58(5):640-3. PubMed ID: 3064798
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of carboplatin and cisplatin in advanced ovarian cancer.
Segelov E; Stuart-Harris R; Bell D; Tattersall M; Hutton-Potts J; Friedlander M
Eur J Gynaecol Oncol; 1994; 15(4):277-82. PubMed ID: 7957335
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of iproplatin in advanced ovarian carcinoma.
Sessa C; Vermorken J; Renard J; Kaye S; Smith D; ten Bokkel Huinink W; Cavalli F; Pinedo H
J Clin Oncol; 1988 Jan; 6(1):98-105. PubMed ID: 3335895
[TBL] [Abstract][Full Text] [Related]
38. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.
Mangioni C; Bolis G; Pecorelli S; Bragman K; Epis A; Favalli G; Gambino A; Landoni F; Presti M; Torri W
J Natl Cancer Inst; 1989 Oct; 81(19):1464-71. PubMed ID: 2674459
[TBL] [Abstract][Full Text] [Related]
39. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
Piccart MJ; Bertelsen K; James K; Cassidy J; Mangioni C; Simonsen E; Stuart G; Kaye S; Vergote I; Blom R; Grimshaw R; Atkinson RJ; Swenerton KD; Trope C; Nardi M; Kaern J; Tumolo S; Timmers P; Roy JA; Lhoas F; Lindvall B; Bacon M; Birt A; Andersen JE; Zee B; Paul J; Baron B; Pecorelli S
J Natl Cancer Inst; 2000 May; 92(9):699-708. PubMed ID: 10793106
[TBL] [Abstract][Full Text] [Related]
40. The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens.
du Bois A; Vach W; Siebert C; Holy R; Ledergerber M; Wechsel U; Kriesinger-Schroeder H
Support Care Cancer; 1997 May; 5(3):212-8. PubMed ID: 9176967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
